Just know, there are over 100 rare cann-a-binoids out there. This could be only the start of something even bigger.
Read The Full Company Presentation Here.
Right now, INM has several potential catalysts to be aware of. Here they are:
No. 1 INM Potential Catalyst - Research Firm Edison Group Provides Huge $20+ Price Target
"Huge" might be an understatement here.
Edison Group slapped a $20.53 price target on INM towards the end of last year which provides this profile with a stunning 1900+% potential upside from Wednesday's closing valuation.
Here's the full report.
No. 2 INM Potential Catalyst - Another Low Float Profile
According to the Yahoo Finance website, INM has a low float.
The website reports this profile to have approximately 13.74Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
No. 3 INM Potential Catalyst - Important Shareholder Update Highlighting Key Accomplishments
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cann-a-binoids, today issued the following letter from President and CEO Eric A. Adams.
Dear Shareholders, Colleagues, and Business Partners,
I’d like to start off by sending you warm wishes for a healthy and prosperous 2022. While another wave of the CV-19 pandemic continues to bring global uncertainty and an ever-evolving business environment, we remain true to our fundamental principles of bringing short- and long-term value to our shareholders.
I’m very excited to provide updates on our progress as we begin to commercialize new products and explore an array of rare cann-a-binoids for their potential therapeutic applications.
Acquisition of BayMedica, Creating a Leader in Rare Cann-a-binoid Manufacturing
The acquisition of BayMedica in October 2021 brings InMed tremendous commercial opportunities and we believe has positioned the Company as a clear leader in rare cann-a-binoid manufacturing. This combination of companies is an excellent match – bringing together synergistic programs and expertise that will accelerate and strengthen the combined cann-a-binoid programs. The acquisition of BayMedica sets the stage for a number of key business initiatives:
- Positions the company as a global leader in the research, development and commercialization of rare cann-a-binoids;
- Provides an immediate revenue stream through the B2B sale of rare cann-a-binoids in the health and wellness sector;
- Strengthens and diversifies our rare cann-a-binoid manufacturing capabilities and expertise with the addition of yeast biosynthesis and chemical synthesis;
- Provides access to proprietary, patent-pending novel cann-a-binoid analogs for pharmaceutical drug development; and
- Adds significant, multifaceted expertise to our team across a variety of research and business functions.
This acquisition was a natural fit. The combination of our pharma-grade manufacturing process, IntegraSyn™, and BayMedica’s revenue-generating, consumer-focused processes that may also be suitable as a basis for pharmaceutical applications, create a strong platform for significant growth in the cann-a-binoid manufacturing space.
BayMedica’s team brings extensive expertise that strengthens both our pharmaceutical drug development efforts and our continued exploration of rare cann-a-binoids. In addition to growing BayMedica’s commercial activities, we continue to focus on the research and development of cann-a-binoid analogs and new chemical entities for pharmaceutical purposes.
IntegraSyn™: Maximizing Production Yield
We continue to make significant strides with our IntegraSyn™ program and hit several milestones throughout 2021. In June, we announced that IntegraSyn™ was capable of producing an industry-leading yield of 5 g/L. This significantly reduces the cost of the manufacturing process, which will enable more efficient large-scale production.
Our goal is to optimize this platform for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cann-a-binoids, with the potential to integrate with BayMedica’s biosynthesis or chemical synthesis manufacturing approaches. With these diverse technologies, we have a breadth of synthetic cann-a-binoid manufacturing capabilities to deliver high-quality, cost-effective rare cann-a-binoids for any segment of the market from consumer packaged goods to prescription pharmaceuticals.
Read the full shareholder update here.
No. 4 INM Potential Catalyst - Company Launches B2B Sales Of CBT
InMed Launches Canna-b-icitran (CBT), Expanding its Rare Cann-a-binoid Portfolio for the Health and Wellness Sector
- CBT is the first of several rare cann-a-binoid launches planned for the first half of 2022; includes CB=DV and TH=CV
- Expands the Company’s rare cann-a-binoid product portfolio, which also includes cann-a-bichromene (CBC)
- Strengthens leadership position in commercial scale production of high demand rare cann-a-binoids
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce it has launched B2B sales of the rare cann-a-binoid cann-a-bicitran (CBT) into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022.
“We are delivering on our objective to launch additional rare cann-a-binoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cann-a-binoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cann-a-binoids in these sectors,” stated Shane Johnson, SVP and General Manager of BayMedica. “The launch of CBT further demonstrates our ability to produce rare cann-a-binoids at commercial scale, an achievement that very few companies have been able to accomplish. We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cann-a-binoids.”
Read the full article here.
Nasdaq Profile Recap - Top 4 INM Potential Catalysts
No. 1 - Research Firm Edison Group Provides Huge $20+ Price Target
No. 2 - Another Low Float Profile
No. 3 - Important Shareholder Update Highlighting Key Accomplishments
No. 4 - Company Launches B2B Sales Of CBT
Coverage is officially initiated on INM. When you have time later, do this: